aap Implantate AG

M&A Activity • Dec 17, 2009

News Details

Corporate | 17 December 2009 16:11

aap sells Analytics Division

aap Implantate AG / Restructure of Company

17.12.2009

Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

aap Implantate AG, a medical technology company listed in the Frankfurt
stock market's Prime Standard segment and active in the fields of medical
biomaterials, fracture healing and joint re-placement, has sold to a Dutch
investor its analytics division, comprising Dutch subsidiaries Bac-timm and
Farmalyse and defined as a non-core business activity since the beginning
of 2009. Both companies have a cumulated Enterprise Value of EUR 3.3
million.

The transaction leads both to improvements in the monetary sector and to
decisive quality benefits for the aap Group. It reduces Group employee
numbers by a further 37, or 24 percent in all compared with December 31,
2008. By selling both companies and on the basis of Ana-lytics sales of
around EUR 2.5 million, aap expects at Group level a decrease of the EBITDA
of around EUR 0.3 million for the fiscal year 2010. The Group's improved
cash position of around EUR 2.3 million and the reduction of the financial
liabilities of around EUR 1.0 million will result in a further optimization
of the debt coverage ratio.

In these difficult economic times the management also attached importance
to the transaction's social compatibility. Both locations are to be
maintained, the management has a share in the company, and all of the
employees have been retained.

After the handover of dental sales to an exclusive distributor, the closure
of the Düsseldorf loca-tion, and the concentration of R&D activities on its
three core business areas, aap has in selling the analytics division
reached a further milestone its strategic realignment to Ortho, Trauma and
Spine business. The sale of the analytics division and the further
reduction in the number of lo-cations that it involves increases the
agility and flexibility of aap. Its consistent strategic focus makes the
business model easier to understand and more attractive for investors.

aap will publish details of its planning for the fiscal year 2010 along
with its interim sales fig-ures in January of next year.
_____________________

aap is a medical technology company that develops, manufactures and markets
biomaterials and implants for trauma and orthopaedics. Its product
portfolio includes bone cements, bone graft substitutes, antibi-otic
carriers, and implants for fracture healing and joint replacement. In
addition to its Berlin HQ the Company has sites in Dieburg and Obernburg
near Frankfurt am Main and Nijmegen in the Netherlands. aap Implantate AG
stock has been listed in the Prime Standard segment of the Frankfurt Stock
Exchange since May 16, 2003.

Contact:
Bei Rückfragen wenden Sie sich bitte an:
aap Implantate AG; Nanette Hüdepohl; Head of Corporate Communications &
Legal Affairs; Lorenzweg 5; D-12099 Berlin
Tel.: ++49/30/750 19 - 133; Fax.: ++49/30/750 19 - 290; n.huedepohl@aap.de

17.12.2009 Ad hoc announcement, Financial News and Media Release distributed by DGAP.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Deutschland
Phone: +49 (0) 30 75 01 90
Fax: +49 (0) 30 75 01 91 11
E-mail: aap@aap.de
Internet: www.aap.de
ISIN: DE0005066609
WKN: 506660
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hannover, München, Hamburg, Stuttgart

End of News DGAP News-Service

---